Articles related to DEPRESSION

The FDA granted Breakthrough Therapy designation to DT120, an oral lysergide formulation under investigation for major depressive disorder, based on phase 3 findings suggesting rapid and sustained antidepressant effects, though the treatment remains investigational and unapproved.

Baseline activity in the left dorsolateral prefrontal cortex and right precuneus during working memory and emotion-regulation tasks was associated with depression severity one year later in young adults at elevated risk for affective disorders, but not with future mania symptoms.

A comprehensive prescribing guide argues that orally administered racemic ketamine may offer a low-cost, accessible option for severe, suicidal, or treatment-resistant depression, while emphasizing structured protocols, monitoring, informed consent, and careful patient selection.

Prior ayahuasca experience was associated with lower self-reported depression, stress, and alcohol use among Brazilian ceremony participants, while also correlating with stronger spiritual wellbeing and metaphysical beliefs in an observational study that did not establish causality.

Physical symptoms following antidepressant cessation are generally transient and consistent with established discontinuation phenomena, while persistent or delayed symptoms remain difficult to explain pharmacodynamically and may involve psychiatric, psychological, or somatic contributors.

Emerging reports suggest some patients experience emotional blunting or reduced reward responsiveness after starting GLP-1 receptor agonists. Current evidence remains mixed, and available data have not established a causal relationship between GLP-1 therapy and diminished antidepressant response.